Results 71 to 80 of about 740 (167)

CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm

, 2023
In spite of consistent progress at the level of basic research and of clinical treatment, acute myeloid leukemia (AML) still represents an unmet clinical need for adult and pediatric patients. To improve the outcomes of these patients, it is necessary to
Elvira Pelosi, Germana Castelli, Ugo Testa   +2 more
core   +1 more source

Venetoclax in the Therapeutic Strategy for BPDCN Management

eJHaem, Volume 6, Issue 4, August 2025.
ABSTRACT Background Venetoclax, a B‐cell lymphoma 2 (BCL‐2) inhibitor, is a promising treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and is currently under evaluation in clinical trials. However, several case reports have reported relapses after prolonged treatment, and development of resistance.
Margaux Poussard, Maxime Fredon, Imane Belakri, Sabeha Biichle, Florian Renosi, Evan Seffar, Morgane Boichut, Romain Boidot, Elodie Bôle‐Richard, Francis Bonnefoy, Marie Kroemer, Sophie Bonnot‐Perrin, Philippe Saas, Olivier Adotévi, Francine Garnache‐Ottou, Fanny Angelot‐Delettre   +15 more
wiley   +1 more source

Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark

, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an uncommon hematologic malignancy with poor outcomes. Existing data on the clinical behavior of BPDCN are limited because reported outcomes are from small retrospective series, and standardized ...
Stevenson, Kristen E, Stone, Richard M, Brunner, Andrew M, Rampal, Raajit K, Lane, Andrew A, Louissaint, Jr, Abner, Haddadin, Michael, Dogan, Ahmet, Neuberg, Donna S, Upadhyay, Vivek A, Horwitz, Steven M, Tallman, Martin S, Fathi, Amir T, Mehta-Shah, Neha, Lovitch, Scott B, Taylor, Justin, Grussie, Erwin   +16 more
core   +1 more source

Clinical management of CMML—State of the art

British Journal of Haematology, Volume 207, Issue 2, Page 350-364, August 2025.
Patients with chronic myelomonocytic leukaemia (CMML) typically present with clinical feature including splenomegaly, constitutional symptoms and autoimmune phenomena, as well as with pathological blood counts and biological features in the marrow. These characteristics may influence the assignment to prognostic categories such as the CPSSmol and also ...
K. Nachtkamp, F. Schulz, N. Gattermann, U. Germing   +3 more
wiley   +1 more source

TP53‐Mutated Acute Myeloid Leukemia: Unanswered Questions

Hematological Oncology, Volume 43, Issue 4, July 2025.
ABSTRACT TP53‐mutated acute myeloid leukemia (AML) remains one of the most treatment‐resistant hematologic malignancies, with poor overall survival despite advancements in therapeutic strategies. The loss of functional p53 compromises DNA repair, apoptosis, and genomic stability, rendering both conventional and novel therapies largely ineffective. This
Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, Caterina Labanca, Giulio Caridà, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Noemi Puccio, Antonino Neri, Fortunato Morabito, Massimo Gentile   +11 more
wiley   +1 more source

Abstract B038: Multi-omic Analyses in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is an aggressive hematologic malignancy with mixed cellular states encompassing dendritic, myeloid, and lymphoid features.
Jingjing Liu, Sankaranarayanan C. Kannan, Hannah C. Beird, Phillip Andrew. Futreal, Arturo Olguin, Axel Künstner, Janice Chen, Jennifer L. Cotton, Marcos C. Estecio, Marina Konopleva, Naveen C. Pemmaraju   +10 more
core   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm–Current Insights

, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare clonal hematologic malignancy of plasmacytoid dendritic cell precursors. The presentation and clinical course of BPDCN is widely heterogeneous and was most recently categorized as a distinct ...
Venugopal, Sangeetha, Lane, Andrew A., Mascarenhas, John, Zhou, Selena, El Jamal, Siraj M.   +4 more
core   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm in the Era of Targeted Therapies

Hemato
Blastic plasmocytoid dendritic cell neoplasm (BPDCN) is a rare myeloid malignancy, characterized by the involvement of multiple organs, including the skin, bone marrow and blood, lymph nodes and the central nervous system.
Ugo Testa
doaj   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results

Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an orphan malignancy defined by the WHO as affection fewer than 65 per 100,000 people and by the U.S. FDA as affecting less than 200,000 people in the U.S..
Attardi, Enrico, Voskanyan, Astghik, Alencar, Alvaro J, Peng, Ching-Tien, Ohannessian, Robin, Konopleva, Marina, Tamamyan, Gevorg, Martelli, Maria Paola, Mehra, Shefali, Bedirian, Karen, Martirosyan, Nare, Komrokji, Rami S., Abramashvili, Mariam, Kotoucek, Pavel P, Ivanyan, Arusyak, Kutluk, Tezer, Tuğcu, Deniz, Papyan, Ruzanna, Alhuraiji, Ahmad, Tekkesin, Funda, Taylor, Justin, Al-Jadiry, Mazin Faisal, Ghali, Hasanein, Voso, Maria Teresa, Su, Min-Yu, Al Ali, Najla H., Badikyan, Maria, Stancioaica, Maria Camelia, Hovsepyan, Shushan, El-Ashwah, Shaimaa, Danelyan, Samvel, Owen, Carolyn, Ghahramanyan, Nerses, Bakhshi, Sameer, Maghaqyan, Hasmik, Kebudi, Rejin, Pemmaraju, Naveen, Bardakhchyan, Samvel, Sergi, Consolato M, Elashwah, Salma, Kazandjian, Dickran, Coriu, Daniel, Totogashvili, Nino   +42 more
core   +1 more source

AML-1127: TRILLIUM: A Phase 2 Multicenter Trial of Tagraxofusp Plus Venetoclax and Azacitidine (VEN/AZA) in Patients Ineligible for Intensive Chemotherapy (IC) With Previously Untreated CD123+ Acute Myeloid Leukemia (AML)

In AML, VEN/AZA is the standard of care for patients unfit for or refusing IC (complete remission [CR], 36.7%; median overall survival [mOS], 14.7 months).
Gupta, Ira, Pemmaraju, Naveen, Sekeres, Mikkael A., Lane, Andrew A., Kantarjian, Hagop M., Daver, Naval G., Fathi, Amir, Garzon, Jessica, Tosolini, Alessandra   +8 more
core   +1 more source